Duchenne Muscular Dystrophy (DMD) Clinical Trial
Official title:
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).
This is an open-label, multi-center study to evaluate the efficacy and safety of eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to exon 51 skipping (treated group), with a concurrent control arm of DMD patients not amenable to exon 51 skipping (untreated group). Following primary efficacy endpoints, dosing will continue to week 144 to evaluate the long term effects of eteplirsen. Patients in the treated group will receive once weekly intravenous (IV) infusions of 30 mg/kg Eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks). Patients in the untreated group will not receive treatment. Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as the six minute walk test. Patients in the treated group will undergo a muscle biopsy at Baseline and a second muscle biopsy over the course of the study. Patients in the untreated group will not undergo muscle biopsy. Safety, including adverse event monitoring and routine laboratory assessments, will be continuously monitored for all patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02814019 -
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
|
Phase 3 | |
| Completed |
NCT01478022 -
To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20
|
Phase 1 | |
| Completed |
NCT00654784 -
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Recruiting |
NCT02614820 -
The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD
|
N/A | |
| Withdrawn |
NCT02036463 -
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT01982695 -
Cardiomyopathy in DMD: Lisinopril vs. Losartan
|
N/A | |
| Recruiting |
NCT05516745 -
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
|
N/A | |
| Completed |
NCT02420379 -
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
| Active, not recruiting |
NCT05135663 -
Extension Study of NS-089/NCNP-02 in DMD
|
Phase 2 | |
| Completed |
NCT01380964 -
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
|
N/A | |
| Completed |
NCT05990608 -
Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT04322357 -
Twice Weekly Steroids and Exercise as Therapy for DMD
|
Phase 2 | |
| Not yet recruiting |
NCT06392724 -
A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
|
Early Phase 1 | |
| Completed |
NCT01540409 -
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Terminated |
NCT04184882 -
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
| Terminated |
NCT04254172 -
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
|
||
| Recruiting |
NCT05524883 -
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
Phase 1/Phase 2 | |
| Completed |
NCT01761292 -
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
|
Phase 1/Phase 2 |